{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030185","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.935094+00:00","generated_at":"2026-05-31T01:10:50.304385+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Avenue Therapeutics awards 235,000 RSUs to CEO MacLean and interim CFO Jin","bullets":["CEO Alexandra MacLean receives 170,000 RSUs; Interim CFO/COO David Jin receives 65,000 RSUs.","RSUs vest in four equal installments on 9/30/24, 12/31/24, 9/20/25, and 9/20/26, subject to continued service.","Settlement deferred until the earlier of Jan 10 after termination of service or a Change in Control.","Awards granted under the company's 2015 Incentive Plan as amended."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030185","json":"https://secwatch.observer/filing/0001437749-24-030185.json","markdown":"https://secwatch.observer/filing/0001437749-24-030185.md","text":"https://secwatch.observer/filing/0001437749-24-030185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924030185/0001437749-24-030185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924030185/atxi20240927_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:10:50.304385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}